TrialBlood advances2018

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).

Gail J Roboz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.